(Q36747250)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

non-alcoholic steatohepatitis

26 December 2019

main subject

steatohepatitis

0 references

1 reference

based on heuristic

inferred from title

author

Evangelos N Liberopoulos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Moses Elisaf

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Andrew Kenneth Burroughs

5

object named as

Andrew K Burroughs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

Maria C Diakou

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Epaminondas V Tsianos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

Dimitri P Mikhailidis

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

publication date

1 February 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

Scandinavian Journal of Gastroenterology

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

139-147

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Insulin resistance in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Cytokines and the pathogenesis of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Plasma adiponectin is decreased in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

New insights in the pathogenesis of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Hepatic effects of dietary weight loss in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Nonalcoholic steatohepatitis: a study of 49 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A phase 2 clinical trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Rosuvastatin as treatment for non alcoholic steatohepatitis (NASH) and highly active antiretroviral therapy (HAART)-dyslipidaemia: new treatment for global dangers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Negative trials in nonalcoholic steatohepatitis: why they happen and what they teach us.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Review article: Drug therapy for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Treatment of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

Serum gamma-glutamyltransferase and risk of type 2 diabetes mellitus in men and women from the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520601058395

10.1080/00365520601058395

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17327932%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference